V. Rossi, L. Grillo, F. D. Cesare, E. Saraco, F. Scardamaglia, F. Svegliati, A. Cortese, L. Vigna
{"title":"How safe is it to administer dual anti-HER2 block with pertuzumab and trastuzumab on a patient with life-threatening liver breast cancer metastasis?","authors":"V. Rossi, L. Grillo, F. D. Cesare, E. Saraco, F. Scardamaglia, F. Svegliati, A. Cortese, L. Vigna","doi":"10.2217/bmt-2020-0019","DOIUrl":null,"url":null,"abstract":"Aim: We report a case of a young woman who presented with HER2+ metastatic breast cancer and visceral crisis to asses safety and effectiveness of dual anti-HER2 plus chemotherapy. Patients & methods/materials & methods: At the time of advanced breast cancer diagnosis, the patient presented in scanty clinical condition with severe liver function tests elevation. First-line chemotherapy based on pertuzumab-trastuzumab plus weekly paclitaxel at 50% reduced dose due to liver dysfunction was administered. Results: Improvement and normalization of liver function tests and patient’s clinical condition was recorded in less than 2 months. Computed tomography revealed a partial remission of liver metastasis. Conclusions: Early initiation of standard HER2 target therapies outweigh the risks of toxicities and can be successfully used also in patients with life-threatening liver breast cancer metastasis.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2020-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2020-0019","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/bmt-2020-0019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 2
Abstract
Aim: We report a case of a young woman who presented with HER2+ metastatic breast cancer and visceral crisis to asses safety and effectiveness of dual anti-HER2 plus chemotherapy. Patients & methods/materials & methods: At the time of advanced breast cancer diagnosis, the patient presented in scanty clinical condition with severe liver function tests elevation. First-line chemotherapy based on pertuzumab-trastuzumab plus weekly paclitaxel at 50% reduced dose due to liver dysfunction was administered. Results: Improvement and normalization of liver function tests and patient’s clinical condition was recorded in less than 2 months. Computed tomography revealed a partial remission of liver metastasis. Conclusions: Early initiation of standard HER2 target therapies outweigh the risks of toxicities and can be successfully used also in patients with life-threatening liver breast cancer metastasis.
期刊介绍：
Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
